GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Net Cash per Share

RVTY (Revvity) Net Cash per Share : $-29.64 (As of Sep. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Revvity's Net Cash per Share for the quarter that ended in Sep. 2024 was $-29.64.

The historical rank and industry rank for Revvity's Net Cash per Share or its related term are showing as below:

RVTY's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6.69
* Ranked among companies with meaningful Price-to-Net-Cash only.

Revvity Net Cash per Share Historical Data

The historical data trend for Revvity's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Net Cash per Share Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.79 -34.10 -57.48 -49.82 -33.13

Revvity Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.84 -33.13 -31.51 -29.18 -29.64

Competitive Comparison of Revvity's Net Cash per Share

For the Diagnostics & Research subindustry, Revvity's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Revvity's Price-to-Net-Cash falls into.



Revvity Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Revvity's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1603.079-5691.926-0)/123.426
=-33.13

Revvity's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

Net Cash per Share (Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1229.778-4848.036-0)/122.091
=-29.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revvity  (NYSE:RVTY) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Revvity Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Revvity's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121